Fidelity National Financial, Inc. (NYSE:FNF)
Fidelity National Financial, Inc. (NYSE:FNF) represented a move of 1.27 percent or $-0.45 per share and closed its previous day trading session at $33.6. 2.23 Million Shares were traded in the last trading session with an Average Volume of 1.22 Million Shares. The stock currently has a Market Capitalization of 9.13 Billion.
Fidelity National Title Group, Inc. is a leading provider of title insurance, specialty insurance and claims management services. FNT is one of the nation’s largest title insurance companies through its title insurance underwriters. FNT also provides flood insurance, personal lines insurance and home warranty insurance through it specialty insurance business. FNT also is a leading provider of outsourced claims management services to large corporate and public sector entities through its minority-owned subsidiary, Sedgwick CMS.
The stock traded between $31.14 and $42.52 over 1-Year time period showing its price to sales ratio of 1.37. Fidelity National Financial, Inc. (NYSE:FNF) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-4.27 and 200-Day Simple Moving Average of $-11.37. Its Price to Free Cash Flow is 20.34 and Price to Book of 1.96.
Analyst’s recommended the stock as 2 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Fidelity National Financial, Inc. (NYSE:FNF) reported its Actual EPS of $0.78/share. The analysts offering Earnings Estimates for the company were believing that Fidelity National Financial, Inc. could bring EPS of $0.79/share. The difference between Actual EPS and Estimated EPS was -0.01 Percent. Thus showing an Earnings Surprise of -1.3 Percent.
Myriad Genetics, Inc. (NASDAQ:MYGN)
In the last trading session, Myriad Genetics, Inc. (NASDAQ:MYGN) added its value by 0.59% closing at the price of $32.24. The stock currently has market capitalization of 2.4 Billion, with average volume of 892.01 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Myriad Genetics, Inc. (NASDAQ:MYGN) is showing beta of 0.42. This particular value of beta suggests that Myriad Genetics, Inc. (NASDAQ:MYGN) has historically moved 42% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Myriad Genetics, Inc. (NASDAQ:MYGN) is at $0.21.
The stock currently has RSI of 38.42. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering innovative products that transform patients’ lives. These products include leading molecular diagnostic tests for hereditary cancer, urological cancer, lung cancer, autoimmune disorders and other diseases. Myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease. Myriad’s hereditary cancer genetic testing, which helps healthcare professionals better manage and tailor medical care. Myriad is expanding their reach and increasing their impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases.
Myriad Genetics, Inc. (NASDAQ:MYGN) topped its 52-week high price of $50.44 on 09/04/18 and 52-Week Low Price of $27.27 on 04/11/18. The Stock currently has P/E (price to earnings ttm) of 157.27 and Weekly volatility of 3.81% and monthly volatility of 5.46% respectively.